home / stock / abscf / abscf message board
Subject | By | Source | When |
---|---|---|---|
Stock Tracker: Latest Ab Science Paris (ABSCF) Headlines AB Science: initiation of a new phase 3 stu | Stock_Tracker | investorshangout | 03/08/2014 9:34:50 PM |
chartguy89: ABSCF 19.62 Stock Charts $ABSCF 1 Month Chart | chartguy89 | investorshangout | 03/05/2014 10:56:04 PM |
Stock Tracker: ABSCF Recent News AB Science: initiation of a new phase 3 study with masitinib in Pro | Stock_Tracker | investorshangout | 03/02/2014 4:23:40 AM |
chartguy89: ABSCF Stock Charts Saturday, February 22, 2014 at 12:18:40 AM $ABSCF Last: +0.92 | chartguy89 | investorshangout | 02/22/2014 5:18:51 AM |
chartguy89: ABSCF Stock Chart 19.62 Saturday, February 8, 2014 00:19:39 AM | chartguy89 | investorshangout | 02/08/2014 5:19:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This rando...
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Commit...